Results 91 to 100 of about 286,222 (357)
RNA Vaccine: novel approach for cancer treatment [PDF]
, 2011 Cancer is still an unsolved puzzle and a major cause of mortality and morbidity in the world. Today, about one in every thousand people is dying due to cancer. No effective agent has yet been found which can cure cancer in its metastatic stage.
Kanika Bhalla +2 more
core +2 more sources
Advanced Functional Materials, EarlyView.Lipid nanoparticles containing messenger RNA are characterized by sedimentation velocity analytical ultracentrifugation using UltraScan's new Custom Grid algorithm to provide multi‐dimensional distributions for partial specific volume (particle density), molar mass, sedimentation, diffusion, and hydrodynamic radius.
Sophia Bird +8 more
wiley +1 more source
Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. [PDF]
, 1986 Kittens immunized with purified native FeLV-gp70 or -gp85 envelope proteins developed ELISA, but not virus neutralizing, antibodies in their serum to both whole FeLV and FeLV-gp70.
Birch, D +3 more
core
Breast Cancer Vaccine: Are We There Yet? [PDF]
, 2012 In lieu of an abstract, here is the article\u27s first paragraph: Breast cancer is the most fatal form of cancer for female population worldwide. National Cancer Institute (NCI) estimates 226,870 females and 2,190 males to be diagnosed with breast cancer
Chablani, Lipika
core +2 more sources
Advanced Functional Materials, EarlyView.PREdicting LNP In Vivo Efficacy (PRELIVE) framework enables the prediction of lipid nanoparticle (LNPs) organ‐specific delivery through dual modeling approaches. Composition‐based models using formulation parameters and protein corona‐based models using biological fingerprints both achieve high predictive accuracy across multiple organs.
Belal I. Hanafy +3 more
wiley +1 more source
OncoImmunologyEradication of cancer cells by the immune system requires extravasation, infiltration and progression of immune cells through the tumor extracellular matrix (ECM).
Sofia Liborio-Ramos +10 more
doaj +1 more source
Understanding Barriers to HPV vaccine uptake in Appalachia [PDF]
, 2020 Every year in seven small counties of Ohio seventy-six people lose their lives to a completely preventable Human Papillomavirus-related cancer. These counties are not random, nor are they an anomaly.
Murphy, Michaela
core
Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction [PDF]
, 2019 Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies.
Bernstein, David I. +5 more
core +1 more source
Advanced Functional Materials, EarlyView.xxxx. ABSTRACT Glioblastoma (GBM) remains one of the most lethal brain cancers, with median survival rarely exceeding 15 months after diagnosis. Interleukin‐12 (IL‐12) is a potent immunostimulatory cytokine capable of reshaping the tumor microenvironment (TME), yet its clinical translation is hindered by systemic toxicity and short half‐life. RNA‐based
Fatima Hameedat +11 more
wiley +1 more source
Advanced Healthcare Materials, EarlyView.Membrane fusion‐inspired nanomaterials offer transformative potential in diagnostics by mimicking natural fusion processes to achieve highly sensitive and specific detection of disease biomarkers. This review highlights recent advancements in nanomaterial functionalization strategies, signal amplification systems, and stimuli‐responsive fusion designs,
Sojeong Lee +9 more
wiley +1 more source